MARKET OUTLOOK The primary goal of UC treatment is to induce and maintain remission with little to no clinical symptoms remaining. Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate patients, whereas IV and subcutaneous TNF-a inhibitors are primarily reserved for moderate to severe patients refractory to conventional treatment or for first-line treatment in the most severe patients. Lack of primary response or loss of response to TNF-a inhibitors is an ongoing concern; however, the IV-delivered CAM inhibitor Entyvio is a recent entry to the treatment armamentarium that offers an alternative mechanism of action for these patients, and has lead to increasing competition among the biologics.
QUESTIONS ANSWERED ·
PRODUCT DESCRIPTION Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.